Erika P. Hamilton, MD

Erika Hamilton, MD, discusses the mechanism of action of emiltatug ledadotin, a B7-H4-directed Dolasynthen antibody-drug conjugate.

Erika P. Hamilton, MD, discusses antibody-drug conjugates in multiple types of breast cancer, and when to use these drugs in sequence.

Erika Hamilton, MD, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive breast cancer.

Erika Hamilton, MD, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive breast cancer.

Erika Hamilton, MD, discusses the different classes of endocrine therapies and how they compare to one another.

Erika Hamilton, MD, discusses how novel endocrine therapies improve treatment for metastatic breast cancer.

Erika Hamilton, MD, discusses some of the most promising endocrine therapies in breast cancer.

Erika P. Hamilton, MD, discusses the patient population with breast cancer enrolled in the TROPION-PanTumor01 trial in relation to the efficacy of datopotamab deruxtecan.

Focusing on HER2+ breast cancer, Erika P. Hamilton, MD, and the Oncology Brothers review data from JBCRG-M06/EMERALD looking at trastuzumab and pertuzumab in combination with eribulin or a taxane in locally advanced or metastatic disease.

Erika P. Hamilton, MD, and the Oncology Brothers review exciting data from DESTINY-Breast06 and discuss its impact on the evolving treatment landscape.

Medical oncologists discuss the INAVO120 study, which is evaluating inavolisib combination therapy in patients with PIK3CA-mutated breast cancer.

The Oncology Brothers and Erika P. Hamilton, MD, discuss the postMONARCH study investigating fulvestrant alone vs fulvestrant plus abemaciclib.

Following ASCO 2024, Erika P. Hamilton, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to review recent updates from the RxPONDER trial investigating the use of AMH levels in premenopausal women.

Following their review of data presented at ESMO 2023, the Oncology Brothers offer their key takeaways on the evolving breast cancer treatment landscape.

Erika P. Hamilton, MD, and the Oncology Brothers offer clinical insights on recent data from KEYNOTE-522 on pembrolizumab in patients with triple-negative breast cancer.

Experts on breast cancer review recent data updates from TROPION-Breast01 on Dato-DXd (datopotamab deruxtecan) in metastatic HR+/HER2- breast cancer.

Erika P. Hamilton, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from KEYNOTE-756 investigating pembrolizumab plus chemotherapy in early-stage ER+/HER2- breast cancer.

Erika P. Hamilton, MD, discusses the updated safety analysis of the DESTINY-Breast03 trial and the patients who were enrolled in the study.

Erika P. Hamilton, MD, discusses the findings from a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

Erika P. Hamilton, MD, discusses the wide-ranging impacts of the introduction of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the next steps following the successful outcomes of the phase 3 DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the key safety and efficacy findings from the phase 3 DESTINY-Breast03 study.

Erika P. Hamilton, MD, discusses the purpose of a safety follow-up analysis for the DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

Erika P. Hamilton, MD, discusses how researchers are addressing unmet needs for patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the evolution of fam-trastuzumab deruxtecan-nxki through its examination in various trials.

Erika P. Hamilton, MD, discusses unmet needs in treatment options for platinum-resistant ovarian cancer due to the challenges of screening, and what treatment options may become viable in the future.

Erika P. Hamilton, MD, discusses the rationale for exploring OP-1250 monotherapy in an open-label first-in-human multi center phase 1/2 study in adult patients with advanced and/or metastatic hormone receptor-positive, HER2-negative breast cancer.

Erika P. Hamilton, MD, discusses the results from a phase II study of abemaciclib plus tamoxifen versus abemaciclib monotherapy in patients with HR-positive, HER2-negative advanced breast cancer.

Hamilton says there are currently not very many "good" drugs for treating these metastases. She adds that the mainstay for treating these metastases is usually some form of radiation therapy, such as whole brain radiation.